RQx Pharmaceuticals, Inc. is a biopharmaceutical company developing broad spectrum antibiotics. The Company endeavors to optimize natural product chemical scaffolds using medicinal chemistry techniques to generate broad spectrum antibiotics. RQx is focused on a novel molecular target for which no antibiotic has been developed. Additionally, RQx has generated proprietary molecules based on a novel chemical scaffold. RQx and its technologies are a strong response to the world’s growing need for new antibiotics (due to resistance) and the lack of success with small molecules over the past 20 years. The Company’s initial products will focus on community and hospital associated infections, including those from gram-negative bacteria. The Company was founded based on important discoveries in Floyd Romesberg’s lab at the The Scripps Research Institute in La Jolla, CA.